A Phase Iiib, Open Study To Evaluate The Immunogenicity, Reactogenicity And Safety Of A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Pharmacodynamics
- Sponsors Pfizer
- 08 Sep 2017 Planned End Date changed from 1 Aug 2018 to 6 Aug 2018.
- 08 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 6 Aug 2018.
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.